Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2020-2024  (8)
  • Lopert, Ruth  (8)
  • Paris : OECD Publishing  (8)
  • London [u.a.] : Routledge
  • Paris : International Transport Forum
  • Social Issues/Migration/Health  (8)
  • Education
  • Industry and Services
  • 1
    Online Resource
    Online Resource
    Exploring the feasibility of monitoring access to novel medicines : A pilot study in EU Member States (2023)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (79 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.151
    Keywords: Social Issues/Migration/Health
    Abstract: Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as availability and affordability, but a more holistic picture is needed. The OECD undertook a pilot study in EU Member States that aimed to determine the utility and feasibility of routine, cross-national monitoring of access to medicines across multiple dimensions. The work included a desk review to define the dimensions of access and associated indicators, followed by an OECD survey to explore the feasibility of collecting and analysing the relevant data for a convenience sample of 15 recently authorised product/indication pairs. This working paper presents key learnings from the desk review and country survey to which 21 EU Member States responded, with a focus on exploring the utility and feasibility of the processes of monitoring and measurement.
    DOI: 10.1787/8c1d16c4-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 2
    Online Resource
    Online Resource
    Developing a set of indicators to monitor the performance of the pharmaceutical industry (2023)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (75 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.157
    Keywords: Pharmaindustrie ; Performance-Messung ; Transparenz ; Stakeholder ; OECD-Staaten ; Social Issues/Migration/Health
    Abstract: The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework.
    DOI: 10.1787/3b5ca61c-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 3
    Online Resource
    Online Resource
    Enhancing competition in on-patent markets (2023)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (80 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.156
    Keywords: Arzneimittel ; Patent ; Wettbewerb ; Arzneimittelmarkt ; Preis ; OECD-Staaten ; Social Issues/Migration/Health
    Abstract: The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that fostering competition in both on- and off-patent markets can improve the efficiency of pharmaceutical spending. Various policies are used to promote competition among off-patent medicines, but generally do not induce competition in on-patent markets. While tendering is widely used for hospital and other institutional purchasing, it is less common for ambulatory care medicines, or where medicines are reimbursed rather than supplied directly. As part of its broader work agenda on “Increasing the transparency of pharmaceutical markets to inform policies”, this paper explores how payers could harness competition to improve the efficiency of spending on medicines still subject to patent protection or regulatory exclusivity. The OECD undertook an extensive analysis consisting of two parts: 1) a quantitative analysis using product-level time series sales data to explore whether therapeutic competition occurs, and, if so, how it has affected prices and volumes over time, based on a sample of countries and therapeutic classes and 2) a review of current practices and policies on pricing, coverage and procurement of on-patent medicines to identify whether these have been influencing competition between alternative therapeutic products. This report presents the key findings from this analytical work.
    DOI: 10.1787/413f2820-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 4
    Online Resource
    Online Resource
    Ökonomie der Arzneimitteltherapiesicherheit : Verbesserung der Arzneimitteltherapiesicherheit durch kollektives Echtzeit-Lernen (2023)
    Paris : OECD Publishing
    Details
    Language: German
    Pages: 1 Online-Ressource (90 p.) , 21 x 28cm.
    Parallel Title: Parallele Sprachausgabe The economics of medication safety: Improving medication safety through collective, real-time learning
    Keywords: Arzneimittel ; Medizinische Behandlung ; Sicherheit ; Gesundheitsökonomik ; OECD-Staaten ; Social Issues/Migration/Health
    Abstract: Durch ungeeignete Arzneimitteltherapien und inadäquate Systeminfrastrukturen, die unzureichende Adhärenz, medikationsbedingte Schäden und Medikationsfehler nach sich ziehen, kommen nur allzu oft Patient*innen zu Schaden. Im OECD-Raum ist möglicherweise ein Zehntel der Krankenhauseinweisungen auf medikationsbedingte Ereignisse zurückzuführen, und bei einem Fünftel der stationär behandelten Patient*innen treten während des Krankenhausaufenthalts medikationsbedingte Schädigungen auf. Die Kosten der vermeidbaren, auf medikationsbedingte Ereignisse zurückzuführenden Hospitalisierungen sowie der längeren Krankenhausaufenthalte aufgrund von vermeidbaren, im Krankenhaus auftretenden medikationsbedingten Schäden belaufen sich im OECD-Raum insgesamt auf mehr als 54 Mrd. USD. Der vorliegende Bericht umfasst vier Teile. Im ersten Teil werden die menschlichen und wirtschaftlichen Kosten medikationsbedingter sicherheitsrelevanter Ereignisse im OECD-Raum untersucht. Der zweite Teil beschreibt Möglichkeiten zur Verbesserung der Verordnungspraxis, der dritte Teil befasst sich mit den neusten Systemen und Maßnahmen zur Verbesserung der Arzneimitteltherapiesicherheit und im vierten Teil folgen Empfehlungen zur Verbesserung der Arzneimitteltherapiesicherheit auf nationaler Ebene.
    DOI: 10.1787/d91edcf5-de
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 5
    Online Resource
    Online Resource
    The economics of medication safety : Improving medication safety through collective, real-time learning (2022)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (87 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.147
    Keywords: Arzneimittel ; Medizinische Behandlung ; Sicherheit ; Gesundheitsökonomik ; OECD-Staaten ; Social Issues/Migration/Health
    Abstract: Poor medication practices and inadequate system infrastructure—resulting in poor adherence, medication-related harms, and medication errors—too often results in patient harm. As many as 1 in 10 hospitalizations in OECD countries may be caused by a medication-related event and as many one in five inpatients experience medication-related harms during hospitalization. Together, costs from avoidable admissions due to medication-related events and added length of stay due to preventable hospital-acquired medication-related harms total over USD 54 billion in OECD countries. This report includes four components; it 1) assess the human impact and economic costs of medication safety events in OECD countries, 2) explores opportunities to improve prescribing practices 3) examines the state-of-the art in systems and policies for improving medication safety, and 4) provides recommendations for improving medication safety at the national level.
    DOI: 10.1787/9a933261-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 6
    Online Resource
    Online Resource
    Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets (2022)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (45 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.146
    Keywords: Arzneimittelmarkt ; Arzneimittel ; Preis ; Transparenz ; Preismanagement ; OECD-Staaten ; Social Issues/Migration/Health
    Abstract: For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations.
    DOI: 10.1787/c9250e17-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 7
    Online Resource
    Online Resource
    Shortages of medicines in OECD countries (2022)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (54 p.) , 21 x 28cm.
    Series Statement: OECD Health Working Papers no.137
    Keywords: Social Issues/Migration/Health
    Abstract: Even in wealthy economies, access to medicines is increasingly affected by medicine shortages – an issue exacerbated with the onset of the COVID-19 pandemic. The aim of this paper was to examine the extent and nature of medicine shortages in OECD countries (pre-COVID-19) and explore the reasons for this growing global problem. Although differences in monitoring mechanisms make multi-country analyses challenging, a sample of 14 OECD countries reported a 60% increase in the number of shortage notifications over the period 2017-2019. While the complexity of pharmaceutical manufacturing and supply chains hampers root cause analyses, available literature suggests that shortages, as reported by marketing authorisation holders, are predominantly due to manufacturing and quality issues. Nevertheless, commercial factors - and the policy settings that influence them - may play an important role. Although several OECD countries have implemented policy measures to mitigate, monitor and prevent shortages, more robust data and further analyses of root causes and effective policy responses are needed. The way forward should involve a global approach that engages all relevant actors and looks beyond the health care sector alone.
    DOI: 10.1787/b5d9e15d-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
  • 8
    Online Resource
    Online Resource
    Challenges in access to oncology medicines : Policies and practices across the OECD and the EU (2020)
    Paris : OECD Publishing
    Details
    Language: English
    Pages: 1 Online-Ressource (108 p.)
    Series Statement: OECD Health Working Papers no.123
    Keywords: Social Issues/Migration/Health
    Abstract: With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide – and sustain – access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and “real world” evidence, and enhancing international collaboration and information sharing to improve countries’ collective capacity to address clinical and economic uncertainties.
    DOI: 10.1787/4b2e9cb9-en
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    MPI Ethno. Forsch.
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...